Qomel Company’s CEO Hisham Alagla said that construction of the new pharmaceutical plant nears completion. Production is expected to begin by the end of 2025. The plant will focus on specialty pharmaceutical products that meet the needs of the Saudi market and add significant value to the company. 
In an interview with Argaam, Alagla added that the H2 2024 results came in line with expectations, despite a 11.5% year-on-year (YoY) decline in net profit. This drop was attributed to zakat provisions related to the share premium, as well as higher operating expenses due to the company’s ongoing expansions, including the construction of the new pharmaceutical plant and the registration of additional medical products with the Saudi Food and Drug Authority (SFDA), which incurs associated registration costs.
Qomel Company’s CEO Hisham Alagla said that construction of the new pharmaceutical plant nears completion. Production is expected to begin by the end of 2025. The plant will focus on specialty pharmaceutical products that meet the needs of the Saudi market and add significant value to the company.
In an interview with Argaam, Alagla added that the H2 2024 results came in line with expectations, despite a 11.5% year-on-year (YoY) decline in net profit. This drop was attributed to zakat provisions related to the share premium, as well as higher operating expenses due to the company’s ongoing expansions, including the construction of the new pharmaceutical plant and the registration of additional medical products with the Saudi Food and Drug Authority (SFDA), which incurs associated registration costs.
